NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered ...
TMCnet

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration ...
Labmate Online

AI analyses 66,000 MRIs to show muscle quality better disease predictor than BMI

Large-scale imaging study reveals that skeletal muscle quality and fat distribution outperform BMI in predicting diabetes, ...

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical TrialSegment featuring Professor Doctor Casper ...

MDxHealth (MDXH) Q1 2026 Earnings Transcript

Pro forma operating loss -- $7.9 million, widened from a pro forma operating loss of $4.7 million in the prior year; ...
Medscape

Specific Risk Factors Make Difficult-to-Treat RA More Likely

Researchers conducted a meta-analysis of 21 studies to find lifestyle factors and comorbidities that raise odds for having ...